Download PDF

1. Company Snapshot

1.a. Company Description

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies.The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health.It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks.


The company sells its products approximately in 40 countries worldwide.It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women.The company was incorporated in 1991 and is headquartered in Lund, Sweden.


Probi AB (publ) is a subsidiary of Symrise AG.

Show Full description

1.b. Last Insights on PROB

Probi AB (publ) has demonstrated resilience and adaptability in the current economic landscape, positioning it well for future opportunities. The company's focus on innovation and strong fundamentals are crucial attributes in navigating the volatile market conditions. With its high-growth potential, Probi AB is well-suited to capitalize on emerging opportunities. Recent market trends, such as the rebound in global markets driven by cooling U.S. inflation and strong bank earnings, are likely to benefit the company.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Exploring Three High Growth Tech Stocks with Promising Potential

Jan -21

Source:

Card image cap

Exploring High Growth Tech Stocks This December 2024

Dec -23

Source:

Card image cap

Exploring High Growth Tech Stocks Including Avalon Technologies And Two Others

Nov -22

Source:

Card image cap

Exploring High Growth Tech Stocks in Sweden October 2024

Oct -24

Source:

Card image cap

Probi AB (OSTO:PROB) Q3 2024 Earnings Call Highlights: Navigating Growth Challenges with ...

Oct -23

Source:

Card image cap

High Growth Tech Stocks in Sweden to Watch This September 2024

Sep -25

Source:

Card image cap

High Growth Tech Stocks in Sweden To Watch This August 2024

Aug -27

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.00%)

6. Segments

Probiotics

Expected Growth: 6%

Probiotics from Probi AB (publ) growth driven by increasing consumer awareness of gut health, rising demand for natural and preventative healthcare solutions, expansion into new markets, and strategic partnerships. Additionally, growing evidence of probiotics' benefits in immune system support and digestive health contributes to the segment's 6% growth.

Royalties

Expected Growth: 6%

Probi AB's 6% royalty growth is driven by increasing demand for probiotics in the food and pharma industries, expansion into new markets, and a growing portfolio of patented strains. Additionally, rising consumer awareness of gut health and wellness, coupled with strategic partnerships and collaborations, contribute to the company's royalty growth.

7. Detailed Products

Probiotics

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Probi AB develops and manufactures probiotics for human health and animal nutrition.

Probi FerroSorb

Probi FerroSorb is a probiotic strain that helps increase iron absorption in the body.

Probi Digestis

Probi Digestis is a probiotic strain that helps maintain a healthy gut microbiome and supports digestion.

Probi Defendum

Probi Defendum is a probiotic strain that helps support the immune system and reduce inflammation.

Probi FerroSorb+

Probi FerroSorb+ is a probiotic strain that helps increase iron absorption and supports healthy red blood cell production.

Probiotics for Animal Nutrition

Probiotics for animal nutrition are designed to support the health and well-being of animals, improving their digestive health and immune system.

8. Probi AB (publ)'s Porter Forces

Forces Ranking

Threat Of Substitutes

Probi AB (publ) operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the growing demand for probiotics and the increasing competition in the market.

Bargaining Power Of Customers

Probi AB (publ) has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Probi AB (publ) relies on a few key suppliers for its raw materials, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate prices mitigate this risk.

Threat Of New Entrants

The probiotics market has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized manufacturing facilities. This makes it difficult for new entrants to enter the market.

Intensity Of Rivalry

The probiotics market is highly competitive, with several established players competing for market share. Probi AB (publ) faces intense competition from companies such as Chr. Hansen, DuPont, and Lallemand.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 3.78%
Debt Cost 3.95%
Equity Weight 96.22%
Equity Cost 6.68%
WACC 6.58%
Leverage 3.93%

11. Quality Control: Probi AB (publ) passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Kamada

A-Score: 5.4/10

Value: 4.9

Growth: 5.7

Quality: 6.8

Yield: 3.1

Momentum: 9.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Pharmanutra

A-Score: 4.2/10

Value: 1.8

Growth: 6.6

Quality: 8.1

Yield: 3.1

Momentum: 0.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Alliance Pharma

A-Score: 4.0/10

Value: 5.0

Growth: 2.9

Quality: 3.6

Yield: 1.9

Momentum: 9.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
InterCure

A-Score: 3.1/10

Value: 9.0

Growth: 2.3

Quality: 2.9

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Probi

A-Score: 2.9/10

Value: 0.6

Growth: 3.0

Quality: 4.2

Yield: 0.0

Momentum: 8.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Benchmark

A-Score: 2.7/10

Value: 6.6

Growth: 2.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

348.0$

Current Price

348$

Potential

-0.00%

Expected Cash-Flows